Therapy Areas: Inflammatory Diseases
Galderma launches two phase II trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin
25 June 2025 - Dermatology specialist Galderma (SWX:GALD) revealed on Wednesday that it has initiated two new phase II clinical trials to evaluate nemolizumab in patients with systemic sclerosis (SSc)...
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
25 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) said on Wednesday that the US Food and Drug Administration (FDA) has granted orphan drug designation for riliprub...
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
25 June 2025 - Hoth Therapeutics Inc (NASDAQ: HOTH), a US-based clinical-stage biopharmaceutical company developing targeted therapies for rare and serious inflammatory conditions, announced on Tuesda...
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
24 June 2025 - Cumberland Pharmaceuticals Inc (NASDAQ: CPIX), a US-based specialty pharmaceutical company, on Monday announced the latest positive results from its Phase 2 FIGHT DMD trial evaluating i...
European Commission approves argenx's VYVGART subcutaneous injection with Halozyme's ENHANZE for CIDP
23 June 2025 - Halozyme Therapeutics Inc (NASDAQ:HALO) announced on Friday that Dutch immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) has received European Commission approval for ...
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
20 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the US Food and Drug Administration has approved Dupixent (dupilumab) as the first targe...